SR59230A
目录号 : GC39725
SR59230A是一种高效、选择性的β3-肾上腺素受体拮抗剂，对β3、β1和β2受体的IC50值分别为40nM、408nM和648nM。
Cas No.:174689-39-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
SR59230A is a potent and selective β3-adrenoceptor antagonist, with IC50 values of 40, 408, and 648nM for β3-, β1-, and β2-receptors, respectively [1]. SR59230A is a novel inhibitor of the Kir2.1 channel, with an IC50 value of 33μM[2]. SR59230A inhibits the phosphorylation and thereby the activation of the mTOR/p70S6K pathway, crosses the blood-brain barrier, and acts on β3 adrenoceptors[3-4]. SR59230A has been widely used to inhibit cancer cell progression and to develop novel combination therapies[5].
In vitro, SR59230A treatment for 72 hours significantly inhibited the proliferation of HUVEC, BRAF mutated 8505 C thyroid carcinoma cells, and U-87 cells with IC50 values of 6.45µM, 13.09µM, and 18.21µM, respectively[6]. Treatment with 10µM SR59230A for 48 hours induced apoptosis in K562, KCL22, HEL and HL60 cells under hypoxic conditions (1% O2)[7].
In vivo, SR59230A treatment via continuous intratumoral injection at a dose of 5mg/kg for 8 consecutive days led to a significant reduction in tumor volume and weight in the melanoma mouse model, and inhibited angiogenesis[8]. For a period of 5 weeks, 50µg of SR59230A (dissolved in DMSO) was injected into the tail vein every 3 days, which significantly inhibited the growth of breast cancer xenograft tumors in mice and reduced the expressions of p-mTOR S2448, p-4E-BP1 (T37/46), and p-mTOR S2481[9].
References:
[1] Kanzler S A, Januario A C, Paschoalini M A. Involvement of β3-adrenergic receptors in the control of food intake in rats[J]. Brazilian Journal of Medical and Biological Research, 2011, 44: 1141-1147.
[2] Kulzer M, Seyler C, Welke F, et al. Inhibition of cardiac Kir2. 1–2.3 channels by beta3 adrenoreceptor antagonist SR 59230A[J]. Biochemical and Biophysical Research Communications, 2012, 424(2): 315-320.
[3] Deng J, Jiang P, Yang T, et al. Targeting β3-adrenergic receptor signaling inhibits neuroblastoma cell growth via suppressing the mTOR pathway[J]. Biochemical and Biophysical Research Communications, 2019, 514(1): 295-300.
[4] Lob H E, Song J, Hurr C, et al. Deletion of p22phox-dependent oxidative stress in the hypothalamus protects against obesity by modulating β3-adrenergic mechanisms[J]. JCI insight, 2017, 2(2): e87094.
[5] Ascone M, Banella C, Amato R, et al. Abstract A048 SR59230A-induced ferroptosis sensitization of Ewing sarcoma cells via Beta-3 adrenergic receptor modulation: A novel therapeutic target[J]. Cancer Research, 2024, 84(17_Supplement): A048-A048.
[6] Bandini A, Biso L, Viaggi C, et al. Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cells[J]. Investigational New Drugs, 2025: 1-11.
[7] Calvani M, Dabraio A, Bruno G, et al. β3-adrenoreceptor blockade reduces hypoxic myeloid leukemic cells survival and Chemoresistance[J]. International Journal of Molecular Sciences, 2020, 21(12): 4210.
[8] Dal Monte M, Casini G, Filippi L, et al. Functional involvement of β3-adrenergic receptors in melanoma growth and vascularization[J]. Journal of molecular medicine, 2013, 91(12): 1407-1419.
[9] Zhou Z, Zhan J, Luo Q, et al. ADRB3 induces mobilization and inhibits differentiation of both breast cancer cells and myeloid-derived suppressor cells[J]. Cell Death & Disease, 2022, 13(2): 141.
SR59230A是一种高效、选择性的β3-肾上腺素受体拮抗剂，对β3、β1和β2受体的IC50值分别为40nM、408nM和648nM[1]。SR59230A是Kir2.1通道的新型抑制剂，IC50值为33μM[2]。SR59230A能通过抑制mTOR/p70S6K通路的磷酸化以阻断活化，并能穿过血脑屏障，作用于β3 肾上腺素受体[3-4]。SR59230A已广泛应用于抑制癌细胞进展及开发新型联合疗法[5]。
在体外，SR59230A处理72小时可显著抑制HUEVC、BRAF突变甲状腺癌细胞和U-87细胞的增殖，IC50值分别为6.45µM、13.09µM和18.21µM[6]。在低氧条件下，使用10µM的SR59230A处理K562、KCL22、HEL和HL60细胞48小时，能在缺氧条件下（1% O2）诱导细胞凋亡[7]。
在体内，连续9日每日瘤内注射5mg/kg剂量的SR59230A，可显著缩小黑色素瘤小鼠模型的肿瘤体积和重量，并抑制血管生成[8]。每3日尾静脉注射50µg剂量的的SR59230A（溶于DMSO）连续5周，能显著抑制乳腺癌移植瘤在小鼠体内的生长，并降低p-mTOR S2448、p-4E-BP1(T37/46)和p-mTOR S2481的表达水平[9]。
| Cell experiment [1]: | |
Cell lines | Human umbilical vein endothelial cells (HUVECs) |
Preparation Method | HUVECs were cultured in MCDB131 medium supplemented with 10% heat-inactivated fetal bovine serum, 2mM L-glutamine, 10U/ml heparin, 10ng/ml epidermal growth factor (EGF), and 5ng/ml basic fibroblast growth factor, at 37 °C, 5% CO2, and 95% humidity. The cells (2×104) were seeded in 24-well sterile plastic plates and allowed to adhere overnight. The cells were treated with SR59230A (0.001, 0.1, 1, 10, and 100μM) for 72 hours, or treated with solvent as a control to assess cell viability. |
Reaction Conditions | 0.001, 0.1, 1, 10, and 100μM; 72h |
Applications | SR59230A treatment inhibited the cell viability of HUVECs cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male C57BL/6J mice |
Preparation Method | Fifty male C57BL/6J mice (8 weeks old) were raised in a standard environment. The mice were injected with B16F10 cells and then received either SR59230A or L-748,337 treatment. SR59230A and L-748,337 were injected intratumorally at a dose of 5mg/kg/day. The treatment began on the 10th day (D10) after tumor cell injection and continued until D18. The length (L) and width (W) of the tumors were measured daily using a vernier caliper, and the tumor volume was calculated as the formula L×W2×0.5. |
Dosage form | 5mg/kg/day for 9 days; intratumoral injection |
Applications | SR59230A treatment decreases the growth of melanoma in xenograft mouse model of B16F10 cells. |
References: | |
| Cas No. | 174689-39-5 | SDF | |
| Canonical SMILES | O[C@@H](CN[C@H]1CCCC2=C1C=CC=C2)COC3=CC=CC=C3CC.O=C(O)C(O)=O | ||
| 分子式 | C23H29NO6 | 分子量 | 415.48 |
| 溶解度 | DMSO: 31.25 mg/mL (75.21 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4069 mL | 12.0343 mL | 24.0685 mL |
| 5 mM | 481.4 μL | 2.4069 mL | 4.8137 mL |
| 10 mM | 240.7 μL | 1.2034 mL | 2.4069 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet